|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial显示文摘AIM To evaluate the effect of sitagliptin vs placebo on histologic and non-histologic parameters of nonalcoholic steatohepatitis(NASH).METHODS Twelve patients with biopsy-proven NASH were randomized to sitagliptin(100 mg daily)(n=6)or placebo(n=6)for 24 wk.The primary outcome was improvement in liver fibrosis after 24 wk.Secondary outcomes included evaluation of changes in NAFLD activity score(NAS),individual components of NAS(hepatocyte ballooning,lobular inflammation,and steatosis),glycemic control and insulin resistance[including measurements of glycated hemoglobin(Hb A1C)and adipocytokines],lipid profile including free fatty acids,adipose distribution measured using magnetic resonance imaging(MRI),and thrombosis markers(platelet aggregation and plasminogen activator inhibitor 1 levels).We also sought to determine the correlation between changes in hepatic fat fraction(%)[as measured using the Iterative Decomposition of water and fat with Echo Asymmetry and Least-squares estimation(IDEAL)MRI technique]and changes in hepatic steatosis on liver biopsy.RESULTS Sitagliptin was not significantly better than placebo at reducing liver fibrosis score as measured on liver biopsy(mean difference between sitagliptin and placebo arms,0.40,P=0.82).There were no significant improvements evident with the use of sitagliptin vs placebo for the secondary histologic outcomes of NAS total score as well as for the individual components of NAS.Compared to baseline,those patients who received sitagliptin demonstrated improved Hb A1C(6.7%±0.4%vs 7.9%±1.0%,P=0.02),and trended towards improved adiponectin levels(4.7±3.5μg/m L vs 3.9±2.7μg/m L,P=0.06)and triglyceride levels(1.26±0.43 mmol/L vs 2.80±1.64 mmol/L,P=0.08).However,when compared with placebo,sitagliptin did not cause a statistically significant improvement in Hb A1C(mean difference,-0.7%,P=0.19)nor triglyceride levels(mean difference-1.10mmol/L,P=0.19)but did trend towards improved adiponectin levels only(mean difference,0.60μg/m L,P=0.095).No significant changes in anthropometrics,liver enzymes,other adipocytokines,lipid profile,thrombosis parameters,or adipose distribution were demonstrated.The MRI IDEAL procedure correlated well with steatosis scores obtained on liver biopsy in both groups at baseline and post-treatment,and the Spearman correlation coefficients ranged from r=0.819(baseline)to r=0.878(post-treatment),P=0.002.CONCLUSION Sitagliptin does not improve fibrosis score or NAS after 24 wk of therapy.The MRI IDEAL technique may be useful for non-invasive measurement of hepatic steatosis. | Tisha R Joy Charles A McKenzie Rommel G Tirona Kelly Summers Shannon Seney Subrata Chakrabarti Neel Malhotra Melanie D Beaton | 2017 | World Journal of Gastroenterology2017，23，1： | 18 |
| 2 | Management of non-alcoholic fatty liver disease in 2015显示文摘There is no single pharmacologic therapy that has been approved to treat nonalcoholic fatty liver disease in the general population. The backbone of therapy currently includes intensive lifestyle modification withestablished targets for diet and weight loss. The use of unsweetened, unfiltered coffee along with limiting high fructose corn syrup have emerged as beneficial dietary recommendations. The use of empiric oral hypoglycemic agents and vitamin E, however, has not been widely accepted. Developing bariatric surgical techniques are promising, but additional studies with long-term follow up are needed before it can be widely recommended. Finally, liver transplantation is an increasingly frequent consideration once complications of endstage disease have developed. The future treatment of those with nonalcoholic fatty liver disease will likely involve a personalized approach. The importance of the gut microbiome in mediating hepatocyte inflammation and intestinal permeability is emerging and may offer avenues for novel treatment. The study of anti-fibrotic agents such as pentoxifylline and FXR agonists hold promise and new pathways, such as hepatocyte cannabinoid receptor antagonists are being studied. With the incidence of obesity and the metabolic syndrome increasing throughout the developed world, the future will continue to focus on finding novel agents and new applications of existing therapies to help prevent and to mediate the progression of nonalcoholic fatty liver disease. | Neel Malhotra Melanie D Beaton | 2015 | World Journal of Hepatology2015，7，30： | 6 |
| 3 | 亚洲地区硫肥经营管理的重要思考显示文摘亚太地区对于植物S营养给农业带来的效益已广为人知.本地区一些主要国家所进行的大量田间试验清楚地表明,投入足够的硫肥给作物所带来的产出是令人满意的.在亚太绝大部分地区,普通过磷酸钙(SSP)多年来一直是当作基本的P肥使用.继续使用这种肥料将自然而然地改善和防止缺硫现象.对中国缺硫土壤的地区和缺硫程度的评估说明,有效硫含量低的土壤决不仅仅在中国南方存在,而且也广泛地分布在中国北方.已有不少报道指出,施用硫肥明显地增加了作物产量.这些作物既包括了粮食作物、蔬菜、水果,还包括了工业用作物和经济作物.对中国历来生产和消费的硫酸铵和过磷酸钙(普钙)的一项调查表明,施用普钙既是土壤的主要P,又是S的来源.近年来, 由于普钙的施用, 每年大约可提供270万吨植物S营养. 尽管普钙的生产预计会逐渐减少, 但这种肥料仍将继续成为中国农田的重要硫源.由于普钙作为一种肥料有着不可避免的缺点,在中国人们注意到了在普钙的普遍施用中存在的问题.比如,在亚太地区足P土壤或持S 力弱或淋S多或淋S(SO4)力强的土壤,普钙就不是一种理想的肥料.基于这些认识,就生产出种种新型的或改良的(缓和的)硫肥.这些肥料主要包括元素硫(S0)的添加.这就需要根据特定土壤P、S肥力状况有选择地安排生产,并激励硫肥生产技术的不断改进.本文列举了许多例子描述了此类作为植物S营养的新型和改良的S肥,阐明了它们的生产、性质和特效.在亚太地区,长期以来把元素S看作作物的有效硫源.它的优点在于其含S成分非常高,运、储、使用既经济又便当,分解缓慢肥效长;与N、P、K肥配合施用时可灵活地调节S 的浓度.本文同时将参比粗粒元素S在农艺上的无效性,介绍了元素S在氧化成SO42-过程中的细度问题. 本文简要介绍了现有的两种商品粒状硫肥(S0)的制造技术.这种肥料的优点是具有一定的分散性,粒径几微米,颗粒大小适中.文章并着重强调了这种含S颗粒肥料在平衡施肥项目中以及作为复合肥(复混肥)配料的优越性.本文同时讨论了从有效硫含量高低悬殊很大的土样中获得的平均值用来估计需硫量,往往会作出过高或过低的判断等问题. | J D Beaton A M Henderson | 2000 | 安徽农业大学学报2000，27，z1： | 5 |
| 4 | Cross-culture adaptation of health-related quality of life measures: literature review and proposed guidelines 显示文摘 | Guillemin F Bombardier C Beaton D | 1993 | J Clin Epidemiol1993，46，12： | 1 |
| 5 | Sulphate formation and extraction from red soil treated with micronized elemental sulphur fertilizer and incubated in closed and open systems显示文摘 | Hu Z Y Beaton J D Cao Z H | 2002 | Communication on Soil Science and Plant Analysis2002，33，1112： | 1 |
| 6 | Gmde-lines for the process of cross - cultural adaptation of self -report measures显示文摘 | Beaton D E Bcnnkardier C Guillemin F | 2000 | Spine2000，25，24： | 1 |
| 7 | 花生-水稻轮作制中不同硫肥的施用效应显示文摘在广东省中等肥力的春花生-晚稻轮作制田中进行了2年3种不同S肥效应试验.结果表明,施用S肥能促进花生和水稻植株的生长发育,获得不同程度的增产效果,花生的增产幅度明显大于水稻.3种不同S肥(硫磺、过磷酸钙和SulFer 95)中以新型S肥SulFer 95的增产效果最好,施用该S肥,花生荚果产量平均提高9.5%,稻谷产量平均提高6.4%. | 陈建生 张发宝 J D Beaton A Henderson | 2000 | 安徽农业大学学报2000，27，z1： | 1 |
| 8 | IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses 显示文摘 | Linterman MA Beaton L Yu D | 2010 | J Exp ned2010，207，2： | 1 |
| 9 | Temperature effects in bio-P removal显示文摘 | Beatons D Vanrolleghem P A Hosten L H | 1999 | Wat Sci & Tech1999，39，1： | 1 |
| 10 | Looking back at design,looking forward to construction显示文摘 | BROWN C D BEATON H R | 1990 | Journal of Management in Engineering1990，6，3： | 1 |
| 11 | Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines 显示文摘 | Guillemin F Bombardier C Beaton D | 1993 | J Clin Epidemiol1993，46，12： | 1 |
| 12 | Minimal clinically important differences : review of methods 显示文摘 | Wells G Beaton D Shea B | 2001 | J Rheumatol2001，28，2： | 1 |
| 13 | Cross-culture adaptation of health-related quality of life measures:literature renew and proposed guidelines显示文摘 | Guillemin F Bombardier C Beaton D | 1993 | J Clin Epidemiol1993，46，12： | 1 |
| 14 | Contrast enhanced ultrasound should be the initial radiological investigation to characterise focal liver lesions 显示文摘 | Beaton C Cochlin D Kumar N | 2010 | Eur J Surg Oncol2010，36，1： | 1 |
| 15 | Comparing the fixation of a novel hollow screw versus aconventional solid screw in human sacra under cyclic loading loading显示文摘 | McLachlin S D Beaton B J Sabo M T | 2008 | Spine2008，33，17： | 1 |
| 16 | Crosultural adaptation of heahh-re- lated quality of' lifemeasures:literature review and proposed guidelines 显示文摘 | Guillemin F Bumbardier C Beaton D | 1993 | Clin Epidemiol1993，46，12： | 1 |
| 17 | The Berkeley Drosophila Genome Project gene disruption project:single p-element insertionsmutating 25 % of vital Drosophila genes 显示文摘 | Spradling A C Stern D Beaton A | 1999 | Genetics1999，153，： | 1 |
| 18 | The Graded Rede- fined Assessment of Strength Sensibility and Prehension: re- liability and validity显示文摘 | Kalsi-Ryan S Beaton D Curt A | 2012 | J Neurotrauma2012，29，5： | 1 |
| 19 | Tissue specific,inducible,and hormonal control of the human UDP-glucuronosyltransferase-1(UGT1) locus显示文摘 | Chen S Beaton D Nguyen N | 2005 | J Biol Chem2005，280，37： | 1 |
| 20 | Guidelines for the process of cross-cultural adaptation of self-report measures显示文摘 | Beaton D E Bombardier C Guillemin F | | 0，，24： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员